Alex Zhavoronkov, CEO of Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine, a leader in next-generation artificial intelligence technologies for drug discovery and biomarker development. He is also the founder of Deep Longevity, Inc, a spin-off of Insilico Medicine developing a broad range of artificial intelligence-based biomarkers of aging and longevity servicing healthcare providers and life insurance industry. In 2020 Deep Longevity was acquired by Endurance Longevity (HK: 0575).
Alex Zhavoronkov, CEO of Insilico Medicine, challenges the cryonics field to revive a mammal from cryostasis. Cryonics is the science of vitrifying and reviving living tissue for preservation. Currently cells and some tissues can be revived, but no organ or mammal has been cryogenically preserved and resuscitated yet. Alex is interested in noble gasses and their potential to achieve rapid cooling and rapid heating under certain pressure and temperature conditions. Figuring this out could help solve the problem of ice crystal formation during cryostasis and reanimation procedures, paving the way for reanimation of a small mammal after preservation.